Stapled LRRK2 Allosteric Polypeptides for Nontoxic Kinase Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ATP competitive kinase inhibitors for LRRK2 lead to kidney abnormalities and lung issues, and alter LRRK2 localization, causing toxicity, while alternative approaches targeting other domains of LRRK2 are needed for therapeutic benefits in neurological diseases.
Innovation Solution
Synthetic stapled polypeptides that mimic the ROC or COR domains of LRRK2, stabilized by cross-linked non-natural amino acids, modulate LRRK2 kinase activity without affecting its subcellular localization, thereby downregulating dimerization and kinase activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ATP competitive kinase inhibitors are used to inhibit LRRK2, then LRRK2 kinase activity is reduced, but kidney abnormalities and lung issues occur due to altered LRRK2 localization
Solution Approach 1:
The patent uses a peptide molecule as an intermediary that binds to the RocCOR domain of LRRK2, preventing dimerization without directly inhibiting the kinase active site. This intermediary approach allows modulation of LRRK2 activity through a different mechanism, avoiding the harmful localization changes caused by ATP competitive inhibitors while still achieving therapeutic inhibition of kinase activity
Solution Approach 2:
The invention changes the mechanism of action from ATP site competition to RocCOR domain binding, altering the molecular parameters of inhibition. By targeting a different domain and using a peptide-based molecule with specific structural properties, the patent achieves kinase activity reduction without the adverse effects on subcellular localization and organ function
2Reliability
If ATP competitive kinase inhibitors are used to inhibit LRRK2, then LRRK2 kinase activity is reduced, but LRRK2 localization is altered causing toxicity
Solution Approach 1:
The peptide acts as a mediator that interferes with LRRK2 dimerization through RocCOR domain binding, serving as an intermediary that modulates activity without triggering the toxic localization changes. This intermediary mechanism preserves normal LRRK2 cellular distribution while achieving therapeutic kinase inhibition
Solution Approach 2:
Instead of directly blocking the kinase active site (the conventional approach), the patent inverts the strategy by targeting the RocCOR dimerization interface. This inverted approach achieves kinase activity reduction through prevention of active dimer formation, rather than direct active site blocking, thereby avoiding the toxic side effects
3Reliability
If alternative approaches targeting other domains of LRRK2 are used, then therapeutic benefits are improved, but precision and specificity of inhibition must be maintained
Solution Approach 1:
The patent applies local quality by designing a peptide with specific structural features (alpha-helical conformation, hydrophobic residues) that are precisely tailored to interact with the RocCOR domain. This localized optimization of molecular properties at the binding interface ensures high specificity for LRRK2 while maintaining therapeutic efficacy
Solution Approach 2:
The patent employs a peptide molecule with optimized hydrophobic and hydrophilic characteristics that facilitate precise binding to the RocCOR domain. The molecular 'fluid dynamics' of the peptide-LRRK2 interaction, governed by hydrophobic effects and hydrogen bonding, ensures high specificity and precision of inhibition
Data Source
AI summary
The present disclosure describes synthetic polypeptides for the inhibition or modulation of the activity of leucine-rich repeat kinase 2 (LRRK2) along with methods of using the same in the treatment of medical conditions, for example neurological diseases or disorders.